Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab
- Indications Ovarian cancer
- Focus Adverse reactions
- 12 Apr 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 12 Apr 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2018.
- 10 Jan 2017 Status changed from not yet recruiting to recruiting.